Downbeat Major Drug Makers – Star Scientific, Inc. (NASDAQ:STSI), Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), Zogenix, Inc. (NASDAQ:ZGNX)
Houston, TX – April 8, 2013 — (Net PR News) – AnotherWinningTrade.com offers its daily alerts and market content newsletter to investors looking for the best information available! AnotherWinningTrade.com provides its subscribers with useful, timely information and exclusive alerts on penny stocks, mid cap stocks and large cap stocks with the potential to deliver gains of 100%-200% or more. We have the top alerts in the industry. To receive our FREE, comprehensive newsletter, visit AnotherWinningTrade.com.
Today’s Stocks in focus are: Star Scientific, Inc. (NASDAQ:STSI), Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), Zogenix, Inc. (NASDAQ:ZGNX)
Star Scientific, Inc. (NASDAQ:STSI) was hit harder over accusations of impropriety after investigations into stock transactions were started. The company, though, later responded with a strong criticism of the trial attorneys piling into the fray and told investors again that lawyers trolling for clients were not the same as lawsuits, let alone proof of any guilt. In addition, while two investors have sued the company, their allegations are reportedly meritless, and Star is expected to defend itself forcefully.
Get A Free Report And Detailed Analysis On STSI CLICK HERE To Read
Star Scientific, Inc. (NASDAQ:STSI) fell -7.95% and closed at $1.39 with the total traded volume of 1.24 million shares. Its opening price was $1.50 and its shares traded within the range of $1.36-$1.50.
This company has earnings per share of -$0.24, with the net profit margin of -611.49% and operating margin of -739.94%. The company now has market cap of about $231.42 million.
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) faced a sharp decline after Fostamatinib failed to show improvements in an X-ray test that measures the progression of joint damage. The company’s partner, AstraZeneca, disclosed that experimental rheumatoid arthritis pill fostamatinib met only one of two goals in a late-stage clinical trial. The news left the future of one of the group’s few advanced pipeline products doubtful.
How Should Investors React To RIGL Now? Find Out In This TREND ANALYSIS REPORT
Rigel Pharmaceuticals, Inc.(NASDAQ:RIGL) plunged -40.24% with the closing price of $4.50. The overall volume in the last trading session was 14.55 million shares. Its fifty two week range was $4.48-$11.44. The total market capitalization remained $392.13 million.
The stock is lagging behind its 52 week high -60.66% and its last month price volatility remained 4.86%. Its beta coefficient was 1.54 with a target price of $9.37. In its share capital, the company has 87.14 million outstanding shares, while 86.80 million shares have been floated in the market.
It has insider ownership of 11.13% with institutional ownership at 62.87%. Earnings per share this year grew 19.74%, while the five year EPS growth rate was +94.33%.
Zogenix, Inc. (NASDAQ:ZGNX) slipped -12.57% and closed at $1.57 in the last trading session, with the overall traded volume of 1.39 million shares. Its 52 weeks high price was $3.30 and it suffered its lowest price of $1.11 in the same period.
How Should Investors Trade ZGNX Now? Don’t Trade ZGNX Until You Read This TREND ANALYSIS REPORT
ZGNX has current ratio of 1.89 and its total debt-to-equity ratio is 1.97. It has market cap of $179.38 million, while its total outstanding shares are 114.62 million.
Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.